Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 6, 2008, Pages 1470-1479

  Duell, Eric J ^a,b   Bracci, Paige M ^c   Moore, Jason H ^b   Burk, Robert D ^d   Kelsey, Karl T ^e   Holly, Elizabeth A ^c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR5; CHOLECYSTOKININ; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; GLUCURONOSYLTRANSFERASE 1A7; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MANGANESE SUPEROXIDE DISMUTASE; RANTES; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC3 PROTEIN;

ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DNA REPAIR; EXCISION REPAIR; EXTRACELLULAR MATRIX; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HORMONE METABOLISM; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DNA-BINDING PROTEINS; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS; SAN FRANCISCO; SMOKING; TUMOR MARKERS, BIOLOGICAL; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 53449101305     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2797     Document Type: Article

References (31)

1. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138-47.
2. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004;20:640-7.
3. Chatterjee N, Kalaylioglu Z, Moslehi R, et al. Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. Am J Hum Genet 2006;79:1002-16.
4. Goodman JE, Mechanic LE, Luke BT, et al. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006;118:1790-7.
5. Millstein J, Conti DV, Gilliland FD, et al. A testing framework for identifying susceptibility genes in the presence of epistasis. Am J Hum Genet 2006;78:15-27.
6. Moore JH, JC Gilbert CT Tsai, et al. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 2006;241:252-61.
7. Moore JH, White BC. Tuning ReliefF for genome-wide genetic analysis. In: Rajapakse JC, editor. Lecture notes in computer science. New York: Springer; 2007. p. 166-75.
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
9. Duell EJ, Bracci PM, Holly EA. Environmental determinants of exocrine pancreatic cancer. In: Pour PM, editor. Toxicology of the pancreas. Boca Raton: CRC, Taylor & Francis; 2005. p. 395-422.
10. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 2006;15:1458-63.
11. Eberle CA, Bracci PM, Holly EA. Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area. Cancer Causes Control 2005;16:1235-44.
12. Holly EA, Eberle CA, Bracci PM. Prior history of allergies and pancreatic cancer in the San Francisco Bay area. Am J Epidemiol 2003;158:432-41.
13. Duell EJ, Holly EA, Bracci PM, et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 2002;94:297-306.
14. 399Gln polymorphism in x-ray repair cross-complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 2002;62:4630-6.
15. Duell EJ, Holly EA. Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women. Am J Epidemiol 2005;161:741-747.
16. Duell EJ, Casella DP, Burk RD, et al. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:726-31.
17. Hoppin JA, Tolbert PE, Holly EA, et al. Pancreatic cancer and serum organochlorine levels. Cancer Epidemiol Biomarkers Prev 2000;9:199-205.
18. Slebos RJ, Hoppin JA, Tolbert PE, et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:1223-32.
19. Holly EA, Chaliha I, Bracci PM, et al. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol 2004;2:510-7.
20. Chan JM, Wang F, Holly EA. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Epidemiol Biomarkers Prev 2005;14:2093-7.
21. Martinson JJ, Chapman NH, Rees DC, et al. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997;16:100-3.
22. Khan SG, Metter EJ, Tarone RE, et al. A new xeroderma pigmentosum group C poly(AT) insertion/deletion polymorphism. Carcinogenesis 2000;21:1821-5.
23. Jiang G, Qu W, Ruan H, et al. Elimination of false-positive signals in enhanced chemiluminescence (ECL) detection of amplified HPV DNA from clinical samples. Biotechniques 1995;19:566-8.
24. Bailey LR, Roodi N, Dupont WD, et al. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998;58:5038-41.
25. Kokoris M, Dix K, Moynihan K, et al. High-throughput SNP genotyping with the Masscode system. Mol Diagn 2001;5:329-340.
26. Wilson AG, di Giovine FS, Blakemore AI, et al. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992;1:353.
27. Hajeer AH, al Sharif F, Ollier WE. A polymorphism at position-403 in the human RANTES promoter. Eur J Immunogenet 1999;26:375-6.
28. Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002;2:455-63.
29. Jiao L, Hassan MM, Bondy ML, et al. The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett 2007;245:61-8.
30. Jiao L, Bondy ML, Hassan MH, et al. Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Det Prev 2006;30:284-91.
31. To MD, Perez-Losada J, Mao JH, et al. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet 2006;38:926-30.